Industry Briefs: August 20, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Antares Vision and Xyntek have formed a partnership for e-pedigree and serialization turnkey capabilities. Read More
Cambrex has agreed to supply an API for a customer’s Phase III program. The agreement is expected to contribute more than $20 million in revenues to Cambrex, which will expand its large-scale multipurpose cGMP assets in 2012 and 2013. Read More
Onyx Scientific and Molecular Profiles have formed an agreement to deliver end-to-end services from initial drug discovery to early- and late-phase manufacturing. Read More
Parker Hannifin has agreed to acquire SciLog, a provider of sensor technology and automated lab-scale and production systems for the biopharmaceutical industry.
FDA has approved Sanofi’s Auvi-Q (epinephrine injection), a voice-activated autoinjector for treating allergic reactions in people who are at risk for anaphylaxis. Read More
Sun Pharmaceutical has agreed to acquire Taro Pharmaceutical. Read More
TG Therapeutics and Rhizen Pharmaceutical have agreed to collaborate on the development and commercialization of Rhizen’s lead product candidate, a novel PI3K delta inhibitor, TGR-1202 (previously referred to as RP5264). Read More
People Notes
Avantor Performance Materials has named John M. Steitz president and CEO. Read More
ChanTest has appointed Chris Mathes as chief commercial officer. Read More
INC Research has named Jamie Macdonald CEO. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
